Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of LTI-291 in healthy middle-aged to elderly adults
NL-OMON24313Phase 1Completed
- Sponsor
- Lysosomal Therapeutics
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pariceract in Parkinson's disease (PD) (5 arms), sponsored by Lysosomal Therapeutics. Primary endpoints: Safety and tolerability endpoints, Pharmacokinetic endpoints and 1 more. Started Sep 2017; status: completed.
02
Drugs
pariceract
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON24313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24313.